囊泡单胺转运体2抑制剂戊苯那嗪的研究进展
|
摘要
戊苯那嗪是一种新型、高选择性囊泡单胺转运体2抑制剂, 2017年4月被美国食品和药物管理局批准用于治疗成人迟发性运动障碍。在为期6周的短期治疗和持续48周的长期治疗临床试验中,戊苯那嗪均显示出对迟发性运动障碍良好的治疗效果,其常见的不良反应有嗜睡和头痛等。
Valbenazine, a novel and highly selective vesicular monoamine transporter 2(VMAT2) inhibitor, was approved by U.S. Food and Drug Administration for treating tardive dyskinesia in adults in April 2017. Clinical trials showed that valbenazine was effective in treating tardive dyskinesia both in 6-week short-term studies and 48-week long-term extension trials, and the common adverse reactions of valbenazine were somnolence, headache, and so on.
Valbenazine, a novel and highly selective vesicular monoamine transporter 2(VMAT2) inhibitor, was approved by U.S. Food and Drug Administration for treating tardive dyskinesia in adults in April 2017. Clinical trials showed that valbenazine was effective in treating tardive dyskinesia both in 6-week short-term studies and 48-week long-term extension trials, and the common adverse reactions of valbenazine were somnolence, headache, and so on.
引文
[1]MARGOLESE HC,CHOUINARD G,KOLIVAKIS TT,et al.Tardive dyskinesia in the era of typical and atypical antipsychotics.Part 1:pathophysiology and mechanisms of induction[J].Can JPsychiatry,2005,50(9):541-547.
[2]JANKOVIC J.Dopamine depleters in the treatment of hyperkinetic movement disorders[J].Expert Opin Pharmacother,2016,17(18):2461-2470.
[3]MULLER T.Valbenazine granted breakthrough drug status for treating tardive dyskinesia[J].Expert Opin Investig Drugs,2015,24(6):737-742.
[4]马俊,万新华.迟发性运动障碍的研究进展[J].中华老年心脑血管病杂志,2017,19(11):1227-1230.
[5]CARBON M,HSIEH CH,KANE JM,et al.Tardive dyskinesia prevalence in the period of second-generation antipsychotic use:a meta-analysis[J].J Clin Psychiatry,2017,78(3):e264-e278.
[6]FDA.Tetrabenazine[EB/OL].(2008-08-15)[2017-09-13].https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021894s013lbl.pdf.
[7]KAUR N,KUMAR P,JAMWAL S,et al.Tetrabenazine:spotlight on drug review[J].Ann Neurosci,2016,23(3):176-185.
[8]JANKOVIC J,CLARENCE-SMITH K.Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders[J].Expert Rev Neurother,2011,11(11):1509-1523.
[9]GRIGORIADIS DE,SMITH E,HOARE SRJ,et al.Pharmacologic characterization of valbenazine(NBI-98854)and its metabolites[J].J Pharmacol Exp Ther,2017,361(3):454-461.
[10]HAUSER RA,FACTOR SA,MARDER SR,et al.KINECT 3:a phase 3 randomized,double-blind,placebo-controlled trial of valbenazine for tardive dyskinesia[J].Am J Psychiatry,2017,174(5):476-484.
[11]FDA.Valbenazine tosylate[EB/OL].(2017-04-11)[2017-09-13].https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf.
[12]翁加俊,于文娟,李华芳.单胺类囊泡转运体2抑制剂治疗迟发性运动障碍研究进展[J].中国神经精神疾病杂志,2018,44(2):125-128.
[13]EIDEN LE.The vesicular neurotransmitter transporters:current perspectives and future prospects[J].FASEB J,2000,14(15):2396-2400.
[14]YAFFE D,FORREST LR,SCHULDINER S.The ins and outs of vesicular monoamine transporters[J].J Gen Physiol,2018,150(5):671-682.
[15]EIDEN LE,WEIHE E.VMAT2:a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse[J].Ann N Y Acad Sci,2011,1216:86-98.
[16]O’BRIEN CF,JIMENEZ R,HAUSER RA,et al.NBI-98854,a selective monoamine transport inhibitor for the treatment of tardive dyskinesia:a randomized,double-blind,placebocontrolled study[J].Mov Disord,2015,30(12):1681-1687.
[17]CORRELL CU,JOSIASSEN RC,LIANG GS,et al.Efficacy of valbenazine(NBI-98854)in treating subjects with tardive dyskinesia and mood disorder[J].Psychopharmacol Bull,2017,47(3):53-60.
[18]KANE JM,CORRELL CU,LIANG GS,et al.Efficacy of valbenazine(NBI-98854)in treating subjects with tardive dyskinesia and schizophrenia or schizoaffective disorder[J].Psychopharmacol Bull,2017,47(3):69-76.
[19]GRIGORIADIS D,COMELLA C,REMINGTON G,et al.Efficacy of valbenazine(NBl-98854)in subjects with tardive dyskinesia:results of a long-term extension study(KINECT 3extension)[J].Neuropsychopharmacology,2016,41:S213-S214.
[20]FACTOR SA,REMINGTON G,COMELLA CU,et al.The effects of valbenazine in participants with tardive dyskinesia:results of the 1-year KINECT 3 extension study[J].J Clin Psychiatry,2017,78(9):1344-1350.
[21]MARDER S,KANE J,FACTOR S,et al.Kinect 4:a phase 3,one-year,open-label trial of valbenazine in participants with tardive dyskinesia[J].Neuropsychopharmacology,2017,42:S396-S397.
[2]JANKOVIC J.Dopamine depleters in the treatment of hyperkinetic movement disorders[J].Expert Opin Pharmacother,2016,17(18):2461-2470.
[3]MULLER T.Valbenazine granted breakthrough drug status for treating tardive dyskinesia[J].Expert Opin Investig Drugs,2015,24(6):737-742.
[4]马俊,万新华.迟发性运动障碍的研究进展[J].中华老年心脑血管病杂志,2017,19(11):1227-1230.
[5]CARBON M,HSIEH CH,KANE JM,et al.Tardive dyskinesia prevalence in the period of second-generation antipsychotic use:a meta-analysis[J].J Clin Psychiatry,2017,78(3):e264-e278.
[6]FDA.Tetrabenazine[EB/OL].(2008-08-15)[2017-09-13].https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021894s013lbl.pdf.
[7]KAUR N,KUMAR P,JAMWAL S,et al.Tetrabenazine:spotlight on drug review[J].Ann Neurosci,2016,23(3):176-185.
[8]JANKOVIC J,CLARENCE-SMITH K.Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders[J].Expert Rev Neurother,2011,11(11):1509-1523.
[9]GRIGORIADIS DE,SMITH E,HOARE SRJ,et al.Pharmacologic characterization of valbenazine(NBI-98854)and its metabolites[J].J Pharmacol Exp Ther,2017,361(3):454-461.
[10]HAUSER RA,FACTOR SA,MARDER SR,et al.KINECT 3:a phase 3 randomized,double-blind,placebo-controlled trial of valbenazine for tardive dyskinesia[J].Am J Psychiatry,2017,174(5):476-484.
[11]FDA.Valbenazine tosylate[EB/OL].(2017-04-11)[2017-09-13].https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf.
[12]翁加俊,于文娟,李华芳.单胺类囊泡转运体2抑制剂治疗迟发性运动障碍研究进展[J].中国神经精神疾病杂志,2018,44(2):125-128.
[13]EIDEN LE.The vesicular neurotransmitter transporters:current perspectives and future prospects[J].FASEB J,2000,14(15):2396-2400.
[14]YAFFE D,FORREST LR,SCHULDINER S.The ins and outs of vesicular monoamine transporters[J].J Gen Physiol,2018,150(5):671-682.
[15]EIDEN LE,WEIHE E.VMAT2:a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse[J].Ann N Y Acad Sci,2011,1216:86-98.
[16]O’BRIEN CF,JIMENEZ R,HAUSER RA,et al.NBI-98854,a selective monoamine transport inhibitor for the treatment of tardive dyskinesia:a randomized,double-blind,placebocontrolled study[J].Mov Disord,2015,30(12):1681-1687.
[17]CORRELL CU,JOSIASSEN RC,LIANG GS,et al.Efficacy of valbenazine(NBI-98854)in treating subjects with tardive dyskinesia and mood disorder[J].Psychopharmacol Bull,2017,47(3):53-60.
[18]KANE JM,CORRELL CU,LIANG GS,et al.Efficacy of valbenazine(NBI-98854)in treating subjects with tardive dyskinesia and schizophrenia or schizoaffective disorder[J].Psychopharmacol Bull,2017,47(3):69-76.
[19]GRIGORIADIS D,COMELLA C,REMINGTON G,et al.Efficacy of valbenazine(NBl-98854)in subjects with tardive dyskinesia:results of a long-term extension study(KINECT 3extension)[J].Neuropsychopharmacology,2016,41:S213-S214.
[20]FACTOR SA,REMINGTON G,COMELLA CU,et al.The effects of valbenazine in participants with tardive dyskinesia:results of the 1-year KINECT 3 extension study[J].J Clin Psychiatry,2017,78(9):1344-1350.
[21]MARDER S,KANE J,FACTOR S,et al.Kinect 4:a phase 3,one-year,open-label trial of valbenazine in participants with tardive dyskinesia[J].Neuropsychopharmacology,2017,42:S396-S397.